KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $85.6 million.

  • Castle Biosciences' Cash & Equivalents fell 9.89% to $85.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.6 million, marking a year-over-year decrease of 9.89%. This contributed to the annual value of $119.7 million for FY2024, which is 21.11% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Cash & Equivalents is $85.6 million, which was up 4.09% from $82.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Cash & Equivalents ranged from a high of $407.0 million in Q1 2021 and a low of $82.2 million during Q2 2025.
  • Over the past 3 years, Castle Biosciences' median Cash & Equivalents value was $91.2 million (recorded in 2023), while the average stood at $94.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 312.54% in 2021, then crashed by 64.89% in 2023.
  • Quarterly analysis of 5 years shows Castle Biosciences' Cash & Equivalents stood at $329.6 million in 2021, then slumped by 62.70% to $122.9 million in 2022, then decreased by 19.61% to $98.8 million in 2023, then climbed by 21.11% to $119.7 million in 2024, then dropped by 9.89% to $85.6 million in 2025.
  • Its Cash & Equivalents was $85.6 million in Q3 2025, compared to $82.2 million in Q2 2025 and $89.7 million in Q1 2025.